MedTrace Logo

Nutrigenomics of Zinc Supplementation in Insulin Secretion and Diabetes

NCT00981448 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 57

Last updated 2022-01-20

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effect of zinc supplementation on insulin secretion by genotype of SLC30A8.

Conditions

Interventions

DIETARY_SUPPLEMENT

Zinc acetate

50mg of elemental zinc to be administered 2 times daily orally for 14 days.

Sponsors & Collaborators

Principal Investigators

  • Alan R Shuldiner, MD · University of Maryland, Baltimore

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2012-04-30
Completion
2012-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00981448 on ClinicalTrials.gov